Caspofungin Acetate 纯度:99.72% 50mg

您好！欢迎来到炼石商城请登录注册兼职小伙伴

我的购物车

Qiagen 凯杰 Biosharp Omega

客服热线 0771-3293894

首页酶、辅酶及抑制剂MCE>

图片仅供参考，请以实物为准

Caspofungin Acetate 纯度:99.72% 50mg

市场价：: 3100.00

促销价：: ¥3100.00

货号：HY-17006

品牌：MCE

配送至：

北京朝阳

支付：账期货到付款

数量：

支 (预计4-5工作日到货(以MCE官网货期为准))

工作时间

周一至周五：9:00-18:00

咨询电话

0771-3293894

在线咨询

: 客服郭恒蔡玉坤曾宪飞技术咨询

浏览了该商品的用户最终购买

RNeasy Mini Kit (50) 50次

3720.00

Plasmid Mini Kit I(200) 200...

576.00

10ul吸头，透明，袋装，可灭菌...

85.80

浏览了该商品的用户还浏览了

QIAfilter Plasmid Maxi Kit (...

3000.00

QIAamp DNA Blood Midi Kit (2...

2680.00

QIAamp UCP Pathogen Mini Kit...

4112.00

商品介绍
商品咨询

Caspofungin Acetate 是一种抗真菌药，能够非竞争性地抑制1，3-β-d葡聚糖合酶的合成。

Description

Caspofungin (Acetate) is an antifungal drug, and noncompetitively inhibits 1,3-β-d glucan synthase activity.

In Vivo

Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1 μM do not have significant alterations in their ERG waveforms, and their retinas have no detectable morphologic changes or loss of cells. At the vitreal concentration of 41 μM, caspofungin reduces the amplitudes of the a-waves, b-waves, and scotopic threshold responses of the ERG and also produces a decrease in the number of cells in the ganglion cell layer^[1]. Caspofungin (8 mg/kg) or amphotericin B at 1 mg/kg given i.p. once daily for 7 days beginning at 30 h after infection resulted in 100% survival through day 28 relative to vehicle control treatment, which results in 100% mortality by day 11 after infectious challenge. Caspofungin reduces recovery of viable Candida from kidney and brain tissues compared to vehicle control treatment on day 5, when control burden peaked. Caspofungin-treated mice dosed with 2 mg/kg or greater have significantly lower brain burden than amphotericin-B-treated mice at day 5. Amphotericin B and caspofungin treatment reduce kidney fungal burden by 1.7 log CFU/g and 2.46 to 3.64 log CFU/g, respectively^[2].

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (82.41 mM)

DMSO : ≥ 83.3 mg/mL (68.65 mM)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8241 mL	4.1206 mL	8.2412 mL
5 mM	0.1648 mL	0.8241 mL	1.6482 mL
10 mM	0.0824 mL	0.4121 mL	0.8241 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (1.71 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (1.71 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (1.71 mM); Clear solution

References

[1]. Mojumder DK, et al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5796-803.

[2]. Flattery, Amy M. et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrobial Agents and Chemotherapy (2011), 55(7), 3491-3497.

Animal Administration ^[2]	Antifungal therapy is initiated at 30 h after infectious challenge and is given by intraperitoneal (i.p.) injection once daily for 7 days. Mice are treated with caspofungin at 1, 2, 4, or 8 mg/kg/day, amphotericin B at 1 mg/kg/day, or vehicle control (sterile distilled water). Efficacy in this model is assessed in 3 ways: by monitoring survival in a group of 10 animals in each treatment group, by monitoring Candida burden in kidney and brain tissues in a second set of treated animals, and by histologically evaluating the kidneys and brains in a third set of treated animals. Mice are euthanized by CO₂ inhalation, and tissues for both culture and histology are sampled at 30 h (vehicle-treated control only) and at days 5 (24 h after 4th dose), 8 (24 h after last dose), 14, 21 (caspofungin-treated only), and 28 after challenge. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Mojumder DK, et al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5796-803. [2]. Flattery, Amy M. et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrobial Agents and Chemotherapy (2011), 55(7), 3491-3497.

Animal Administration
^[2]

Antifungal therapy is initiated at 30 h after infectious challenge and is given by intraperitoneal (i.p.) injection once daily for 7 days. Mice are treated with caspofungin at 1, 2, 4, or 8 mg/kg/day, amphotericin B at 1 mg/kg/day, or vehicle control (sterile distilled water). Efficacy in this model is assessed in 3 ways: by monitoring survival in a group of 10 animals in each treatment group, by monitoring Candida burden in kidney and brain tissues in a second set of treated animals, and by histologically evaluating the kidneys and brains in a third set of treated animals. Mice are euthanized by CO₂ inhalation, and tissues for both culture and histology are sampled at 30 h (vehicle-treated control only) and at days 5 (24 h after 4th dose), 8 (24 h after last dose), 14, 21 (caspofungin-treated only), and 28 after challenge.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Mojumder DK, et al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5796-803.

[2]. Flattery, Amy M. et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrobial Agents and Chemotherapy (2011), 55(7), 3491-3497.

Molecular Weight	1213.42
Formula	C₅₆H₉₆N₁₀O₁₉
CAS No.	179463-17-3
SMILES	OC1=CC=C(C=C1)[C@H]([C@@H]([C@@H]2NC([C@@H]3C[C@H](CN3C([C@H]([C@H](O)C)NC([C@H](C[C@H]([C@@H](NCCN)NC([C@@H]4[C@H](CCN4C([C@H]([C@H](O)CCN)NC2=O)=O)O)=O)O)NC(CCCCCCCCC(CC(CC)C)C)=O)=O)=O)O)=O)O)O.OC(C)=O.OC(C)=O
Storage	-70°C
Shipping	Room temperature in continental US; may vary elsewhere